New combo therapy offers hope for Tough-to-Treat lymphoma
NCT ID NCT06464185
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This study tests a new treatment for people with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The treatment combines two immune-based approaches: a bispecific antibody and CAR-T cells, aiming to boost the body's ability to fight the cancer. The study involves 48 participants and focuses on safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Conditions
Explore the condition pages connected to this study.